These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34351422)

  • 1. Development of an LC-MS/MS Method for Measurement of Irinotecan and Its Major Metabolites in Plasma: Technical Considerations.
    Aoullay Z; Van Wijk XMR; Yanhui M; Meddah B; Lynch KL; Cherrah Y; Wu AHB
    Lab Med; 2022 Jan; 53(1):47-52. PubMed ID: 34351422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients.
    Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Puangpetch A; Prommas S; Sirilerttrakul S; Rerkarmnuaychoke B; Wongwaisayawan S; Sukasem C
    J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28393405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of an UPLC-MS/MS method for the determination of irinotecan (CPT-11), SN-38 and SN-38 glucuronide in human plasma and peritoneal tumor tissue from patients with peritoneal carcinomatosis.
    Gasthuys E; van Ovost J; Vande Casteele S; Cosyns S; Ceelen W; Van Bocxlaer J; Vermeulen A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Feb; 1233():123980. PubMed ID: 38215697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of Irinotecan and its two major metabolites using a liquid chromatography-electrospray ionization tandem mass spectrometric.
    Zhang W; Dutschman GE; Li X; Ye M; Cheng YC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct; 877(27):3038-44. PubMed ID: 19648066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A validated UPLC-MS/MS method to determine free and total irinotecan and its two metabolites in human plasma after intravenous administration of irinotecan hydrochloride liposome injection.
    Zhuang Q; Liu X; Sun Z; Wang H; Jiang J
    J Pharm Biomed Anal; 2019 Jun; 170():112-123. PubMed ID: 30921645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of irinotecan and its metabolite SN-38 in rabbit plasma and tumors using a validated method of tandem mass spectrometry coupled with liquid chromatography.
    Park DJ; Won JH; Cho AR; Yun HJ; Heo JH; Hwhang TH; Lee DH; Kim WM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 962():147-152. PubMed ID: 24927278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative determination of liposomal irinotecan and SN-38 concentrations in plasma samples from children with solid tumors: Use of a cryoprotectant solution to enhance liposome stability.
    Nair S; Selvo NS; Stolarski A; Klee B; Federico SM; Stewart CF
    J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Sep; 1245():124273. PubMed ID: 39146822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fast liquid chromatography-tandem mass spectrometry method for routine assessment of irinotecan metabolic phenotype.
    Corona G; Elia C; Casetta B; Toffoli G
    Ther Drug Monit; 2010 Oct; 32(5):638-46. PubMed ID: 20683392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma.
    Owens TS; Dodds H; Fricke K; Hanna SK; Crews KR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 May; 788(1):65-74. PubMed ID: 12668072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic study.
    Marangon E; Posocco B; Mazzega E; Toffoli G
    PLoS One; 2015; 10(2):e0118194. PubMed ID: 25689738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid chromatographic-tandem mass spectrometric assay for the simultaneous quantification of Camptosar and its metabolite SN-38 in mouse plasma and tissues.
    Bardin S; Guo W; Johnson JL; Khan S; Ahmad A; Duggan JX; Ayoub J; Ahmad I
    J Chromatogr A; 2005 May; 1073(1-2):249-55. PubMed ID: 15909526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT.
    Kurita A; Kaneda N
    J Chromatogr B Biomed Sci Appl; 1999 Mar; 724(2):335-44. PubMed ID: 10219676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitive determination of irinotecan (CPT-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry.
    Ragot S; Marquet P; Lachâtre F; Rousseau A; Lacassie E; Gaulier JM; Dupuy JL; Lachâtre G
    J Chromatogr B Biomed Sci Appl; 1999 Dec; 736(1-2):175-84. PubMed ID: 10676997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analytical method for irinotecan (CPT-11) and its metabolites using a high-performance liquid chromatography: parallel detection with fluorescence and mass spectrometry.
    Sai K; Kaniwa N; Ozawa S; Sawada J
    Biomed Chromatogr; 2002 May; 16(3):209-18. PubMed ID: 11920947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
    Slatter JG; Schaaf LJ; Sams JP; Feenstra KL; Johnson MG; Bombardt PA; Cathcart KS; Verburg MT; Pearson LK; Compton LD; Miller LL; Baker DS; Pesheck CV; Lord RS
    Drug Metab Dispos; 2000 Apr; 28(4):423-33. PubMed ID: 10725311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A liquid chromatography/electrospray ionization mass spectrometry (LC-MS/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples.
    D'Esposito F; Tattam BN; Ramzan I; Murray M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Nov; 875(2):522-30. PubMed ID: 18952506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shengjiang Xiexin Decoction Alters Pharmacokinetics of Irinotecan by Regulating Metabolic Enzymes and Transporters: A Multi-Target Therapy for Alleviating the Gastrointestinal Toxicity.
    Guan HY; Li PF; Wang XM; Yue JJ; He Y; Luo XM; Su MF; Liao SG; Shi Y
    Front Pharmacol; 2017; 8():769. PubMed ID: 29163158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies.
    Escoriaza J; Aldaz A; Castellanos C; Calvo E; Giráldez J
    J Chromatogr B Biomed Sci Appl; 2000 Apr; 740(2):159-68. PubMed ID: 10821401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics.
    Goldwirt L; Lemaitre F; Zahr N; Farinotti R; Fernandez C
    J Pharm Biomed Anal; 2012 Jul; 66():325-33. PubMed ID: 22551773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
    Rothenberg ML; Kuhn JG; Schaaf LJ; Rodriguez GI; Eckhardt SG; Villalona-Calero MA; Rinaldi DA; Hammond LA; Hodges S; Sharma A; Elfring GL; Petit RG; Locker PK; Miller LL; von Hoff DD
    Ann Oncol; 2001 Nov; 12(11):1631-41. PubMed ID: 11822765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.